Chemed Corporation CHE

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Chemed has logged a 20.9% gain year to date, which puts a spotlight on whether the current share price lines up with the cash the business is expected to generate. With investors weighing both its healthcare hospice operations and its Roto-Rooter services arm, the central issue is what that mix of businesses is really worth when you focus on its cash flows. The stock is up 20.9% year to date, so anyone looking at Chemed today is effectively asking if that move already reflects the cash the...

Chemed Corporation (NYSE:CHE) announced on September 16 that its Roto-Rooter Services Company subsidiary had acquired the largest independent Roto-Rooter franchise for $60.6 million. The California territories serve approximately 11 million people, and the franchise generated annual revenue of $50 million to $55 million before the acquisition. For Chemed Corporation (NYSE:CHE), the purchase price represents approximately […]

CINCINNATI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired the largest independent Roto-Rooter franchise, serving a population of approximately 11 million people, for $60.6 million. Prior to the acquisition, this franchise had annual revenue of between $50.0 and $55.0 million. The territories acquired include Northern San Diego, Palm Springs, Ventura, Bakersfield, Lancaster, Fresno,

CINCINNATI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2026 Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at approximately 10:55 a.m. (CT) at the 1 Hotel in Nashville. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within

OPCH vs. CHE: Which Stock Is the Better Value Option?

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

CINCINNATI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, payable on September 3, 2026, to shareholders of record as of August 17, 2026. This is a 10-cent, or 17%, increase over the 60-cent dividend paid in June 2026. This represents the 221st consecutive quarterly dividend paid by Chemed in its 55 years as a public company. Listed on the New

Chemed Corporation recently reported past second-quarter 2026 results showing higher net income of US$67.7 million, with both basic and diluted EPS from continuing operations rising compared with a year earlier. Alongside these earnings, Chemed continued a long-running capital return program with additional buybacks and now has repurchased over US$2.91 billion of its shares since 2011, while facing renewed pressure from activist investor Barington Capital to review its strategy and...

Healthcare services company Chemed Corporation (NYSE:CHE) announced better-than-expected revenue in Q2 CY2026, with sales up 8.8% year on year to $673.3 million. Its non-GAAP profit of $6.06 per share was 8.2% above analysts’ consensus estimates.